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Be = B effector (cells); IFN = interferon; IL = interleukin; NF = nuclear factor; sIFNgR = soluble recombinant IFNgR; STAT = signal transducer and
activator of transcription; Th = T helper (cells); TNF = tumor necrosis factor.
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Introduction
Cytokines play a critical role in regulating lymphoid cell
responses to most antigenic stimuli, and it is therefore very
likely that these molecules profoundly affect the pathogene-
sis of autoimmune diseases. Consequently, investigations of
the role of cytokines as effectors or predisposing elements
in these diseases have received prominent attention for
many years. Early findings from such studies, however, were
frequently contradictory and, more importantly, difficult to
incorporate into a conceptual framework. A new impetus in
this area was provided by the discovery of Mosmann and
colleagues that T cells could be conveniently divided into
two main subsets, ie Th1 and Th2, with distinct arrays of
cytokine secretion patterns and functions [1,2]. A hypothesis
was subsequently formulated according to which cell-medi-
ated autoimmune diseases, such as insulin-dependent dia-
betes mellitus, are induced by Th1 cells and their cytokines,
and humorally-mediated autoimmune diseases, such as sys-
temic lupus erythematosus, are induced by Th2 cells and
their cytokines. As reviewed below, findings on the primary
role of IFN-g in the pathogenesis of murine lupus and other
observations clearly refute this hypothesis.
Type 1 and Type 2 cells and their cytokines
Many studies have now clearly established that, after
antigen recognition, cytokines at the priming site, together
with other factors such as the type of antigen-presenting
cell, antigen dose, expressed costimulatory molecules,
affinity, and duration of exposure, direct a polarized differ-
entiation of a T helper cell clone into either the Th1 or the
Th2 type [2–5] (Fig. 1). Th1 cells secrete IL-2, IFN-g, and
TNF-b, while Th2 cells secrete IL-4, IL-5.
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IL-10, and IL-13. Th1 cells protect against intracellular
pathogens, activate phagocytes, induce IgG2a antibodies,
and promote delayed-type hypersensitivity responses,
whereas Th2 cells protect against extracellular pathogens,
activate eosinophils, induce IgE-mediated allergic reac-
tions, and promote other humoral responses in which IgG1
predominates. Certain cell-surface molecules have been
reported to be differentially expressed in these two
subsets, including the chemokine receptors CCR5,
CXCR3, and CCR1 on Th1 cells and CCR3 and CCR4 on
Th2 cells [6]. Some of these markers are not specific, since
they are not exclusive to one or the other subset. For
example, CCR5 and CXCR3 are also expressed by Th2
cells, albeit at lower levels than by Th1 cells [7]. Moreover,
a recently identified unique T-cell subtype does not fit
either the Th1 or Th2 definition, and yet it expresses
CXCR5 and preferentially localizes in B-cell follicles, where
it provides help for antibody responses [8,9]. In addition to
certain chemokine receptors, both IL-12Rb2 [10–12] and
IL-18R [13] are selectively expressed by Th1 cells.
Similar Th1- and Th2-like polarized cytokine secretion pat-
terns have now been described for CD8+ and g T cells,
natural killer cells, dendritic cells, macrophages, mast cells,
eosinophils, and even B cells [14]. With regard to the
latter, it was recently found that naïve B cells that were
stimulated in an antigen-dependent fashion with polarized,
cytokine-secreting T effector cells could be induced to dif-
ferentiate into two types of B effector cells, ie Be1, secret-
ing IFN-g (and other cytokines), and Be2, secreting IL-4
(and other cytokines) [15]. Moreover, IFN-g secreted by
Be1 cells and IL-4 secreted by Be2 cells, while presenting
antigen to naïve T cells, regulated Th1 and Th2 develop-
ment, respectively. In recognition of the fact that specific
patterns of cytokine production are now applicable to many
cell types, the main types of cytokine polarization are now
defined as type 1 or type 2 rather than Th1 and Th2 [14].
Apparently, the immune system employs the same overall
pattern of cytokine production regardless of the cell type
involved in a particular response or setting. Therefore, the
assumption that effects observed in a particular disease
after treatment with cytokine agonists or antagonists are
mediated by the corresponding subset of T cells is an over-
simplification. In fact, a variety of other cellular components
might be engaged, either directly or indirectly.
The molecular events associated with type 1 or type 2
cytokine polarization have not been fully elucidated. It is
known that Th1 differentiation driven by IL-12 (a product
of activated macrophages and dendritic cells) requires the
IL-12-responsive signal transducer and activator of tran-
scription (STAT)4, while Th2 differentiation requires the
IL-4-responsive transcription factor STAT6 (Fig. 1) [16].
IL-18 acts synergistically with IL-12 in inducing IFN-g pro-
duction, but signalling by IL-18 is mediated by the IL-1
receptor-associated kinase pathway, not STAT4, leading
to the nuclear translocation of the NF-kB complex selec-
tively in Th1 cells [17]. Additional proto-oncogenes,
kinases, and transcription factors have been implicated in
Th1/Th2 differentiation, including the interferon regulatory
Figure 1
Schematic representation of Th1/Th2 differentiation. Modes of induction, important transcription factors and acquisition or markers are depicted
(for details, see text).Arthritis Research    Vol 3 No 3 Theofilopoulos et al
factor 1 and the T-box expressed in T cell protein for Th1
cells, and the c-Maf proto-oncogene and the GATA3 zinc
finger protein for Th2 cells [16]. Moreover, the JNK/MAP
kinase pathway is induced in Th1 but not Th2 effector
cells [18].
IFN-g g in lupus immunopathology
We and others have used a variety of techniques to
measure cytokine levels in lymphoid organs and affected
tissues of mice predisposed to lupus and have catalogued
a variety of perturbations, with some cytokines upregu-
lated and others downregulated compared with controls
[19]. The most consistent result was high levels of IFN-g,
particularly at the late stages of the disease, with the most
abundant levels being observed in the MRL-Faslpr lupus
strain [20–25]. These increases in IFN-g were docu-
mented at both the RNA and protein levels, as well as by
ELISPOT assays and by cloning kidney-infiltrating T cells.
Increased expression of IL-12 in kidney-infiltrating
mononuclear cells and tubular epithelial cells of
MRL-Faslpr mice have also been reported [26–28].
In addition to spontaneous mouse models of lupus, trans-
genic mice with a normal background overexpressing
IFN-g in the epidermis (under the involucrin promoter)
developed inflammatory skin disease, as well as a T-cell-
dependent lupus-like syndrome with antinuclear autoanti-
bodies and kidney deposits of immune complexes [29,30].
Concentrations of IFN-g and IL-12 are also increased in
the serum of lupus patients, particularly those in the active
stages of the disease [31,32]. Moreover, in such patients,
increases in the Th1/Th2 ratio have been detected in the
peripheral mononuclear cells, and a predominance of Th1
cells is particularly evident in the blood and kidneys of
patients with diffuse proliferative nephritis [33]. Mutations
in the IFN-gR1 and R2 have been identified in some lupus
patients, and a combination of the IFN-gR1 Met14/Val14
with the IFN-gR2 Gln64/Gln64 genotypes has been sug-
gested to be a risk factor for this disease [34]. Nonethe-
less,  in vitro experiments have shown higher IFN-g
expression in peripheral blood mononuclear cells of lupus
patients than in controls after mitogenic stimulation [35].
Of interest is the observation that severe lupus-like
disease was induced in some patients treated with IFN-g
for unrelated autoimmune diseases or myeloproliferative
disorders [36,37].
The importance of IFN-g in lupus pathogenesis (Table 1)
was first suggested by the earlier studies of Jacob et al
[38], who found accelerated disease in [New Zealand
Black (NZB) × New Zealand White (NZW)]F1 ( B×W )
lupus mice receiving IFN-g or its inducers, while those
receiving anti-IFN-g antibody at an early stage had signifi-
cantly delayed onset. Extending these initial observations,
Ozmen et al [39] treated B × W mice with soluble recom-
binant IFN-gR (sIFN-R) or IFN-g, or with anti-IFN-g antibody
commencing at 4 months of age. All the mice treated with
sIFN-gR or anti-IFN-g antibody were alive at approximately
9.5 months, with reduced serologic and histologic disease
parameters, while those receiving IFN-g exhibited earlier
mortality than controls. Treatments with sIFN-gR or anti-
IFN-g antibody were effective only if initiated early in the
disease process, perhaps because of the lack of adjust-
ments in dosage, which might have been inadequate to
neutralize the very high levels of the ligand attained at later
disease stages. In contrast to the studies just mentioned,
other studies showed that treatment with monoclonal anti-
body to IFN-g did not affect the severity of disease or the
survival of MRL-Faslpr mice [40], perhaps because of an
inadequate dose of the antibody or its inability to reach
inflammatory sites.
Definitive evidence that IFN-g is required for pathogenesis
in murine lupus was provided in a series of studies with
MRL-Faslpr or B × W mice in which the IFN-g or IFN-gR
gene had been deleted [41–44]. These studies uniformly
reported significant reduction of histologic and serologic
disease characteristics and extended survival. The authors
of one of these studies [42] made two notable observa-
tions. First, they found that hypergammaglobulinemia was
maintained in MRL-Faslpr mice in which the IFN-g gene had
been deleted, with a switch from IgG2a to IgG1 predomi-
nance, but that the dramatic decrease in levels of the pre-
dominant IgG2a anti-dsDNA autoantibodies was not
associated with a compensatory increase in IgG1 anti-
dsDNA subclass autoantibodies. A second, remarkable,
finding was that glomerulonephritis and early death were
prevented even in mice heterozygous for this deletion
(IFN-g+/–; that is, with about 50% reduction in IFN-g con-
centrations), even though autoantibody levels and renal
deposits of immune complexes were the same as those in
the wild-type MRL-Faslpr mice [42]. These important find-
Table 1
Studies documenting the detrimental effects of IFN-g in murine
systemic lupus erythematosus
Strain Experimental manipulations References
(CBA × C57/BL10)F1 trIFN-g [29,30]
B × W IFN-g [38,39]
B × W Anti-IFN-g mAb [38]
B × W sIFN-gR [39]
B × W IFN-gR–/– [43]
MRL-Faslpr sIFN-gR/Fc [47]
MRL-Faslpr IFN-g–/– [41,42]
MRL-Faslpr IFN-gR–/– [44]ings suggest that therapeutic interventions to reduce IFN-g
levels in lupus may selectively affect certain autoimmune
responses without significantly compromising the capacity
to respond to exogenous antigens. Further, even partial
reduction in IFN-g might curtail its deleterious effects
locally in the afflicted organs. Similar uncoupling phenom-
ena between autoantibody production and local inflamma-
tory responses have been described in B × W mice in
which the gene for the FcRg-chain had been deleted [45].
Moreover, our genome-wide studies have shown that
some loci associated with glomerulonephritis or mortality
do not cosegregate with those associated with the pro-
duction of anti-dsDNA autoantibody [46], indicating that
other autoantibody specificities or additional locally acting
mechanisms may be necessary for the development of
glomerulonephritis. Overall, the findings suggest that IFN-g
may exert disease-promoting effects at both a systemic,
humorally-mediated axis and a local, cell-mediated axis.
Treatment of murine lupus with cDNA
encoding IFN-g gR/Fc
Encouraged by the beneficial effects of experiments
blocking IFN-g in murine lupus, we developed a new strat-
egy to intercept the activity of this molecule by intramuscu-
lar injections of a nonviral vector containing cDNA
encoding the IFN-gR/IgG1Fc fusion protein [47]. We used
this inhibitor instead of the truncated receptor alone,
because fusion molecules secreted as disulfide-linked
homodimers have been shown to have much longer half-
lives than the truncated IFN-gR (40 vs 1–3 h, respectively)
[48,49], and dimeric IFN-gR/Fc fusion protein shows
higher ligand avidity than single-chain receptors [50]. This
therapy significantly reduced serum levels of IFN-g and all
disease parameters in MRL-Faslpr mice when it was initi-
ated before appearance of the disease, particularly when
expression of this biomolecule was enhanced by electro-
poration at the injection site. Remarkably, this treatment
arrested and often ameliorated disease even when the
treatment was initiated when the disease was at an
advanced stage, an unprecedented result. It is impressive
that inhibition of a single molecule has such a profound
effect on this multifactorial disease.
Because of the highly pleiotropic properties of IFN-g, it is
very difficult to identify the exact mechanism(s) by which
blockade of this molecule curtails the development of
murine lupus. The most likely possibility is reduced expres-
sion of MHC class I and II molecules on both mononuclear
and tubular epithelial cells, leading to inefficient self-
peptide presentation and responses [42]. Additional
mechanisms may include reduced expression of other
inflammatory molecules, such as intercellular adhesion
molecule 1 and monocyte chemoattractant protein-1 [47].
The delivery of IFN-g inhibitory molecules by intramuscular
injection of plasmid vectors is simple, and appears to be
nontoxic and safe. This approach for gene therapy of lupus
circumvents several problems encountered with viral
vectors [51], and may have advantages over the use of
sIFN-gR, such as provision of a depot of genetic material
for long-term expression of a biomolecule as well as its
expression in afflicted organs due to migration of the
injected DNA to distant sites [52].
Th2 cytokines in lupus
Although demonstrations of the primary role of IFN-g in the
pathogenesis of murine lupus challenge the Th1/Th2 para-
digm in autoimmunity, this finding should not be taken as
evidence that Th2 cytokines are without influence in this
disease. On the contrary, several studies have shown that
manipulation of IL-4, IL-6, or IL-10 can also affect the pro-
gression of murine lupus. For example, treatment of B × W
or MRL-Faslpr mice with IL-4R or anti-IL-4 antibody
resulted in reduced mortality and disease [53,54]. Con-
versely, IL-4 was shown not to be a necessary component
in the BXSB male lupus disease [55] and, as a further
complication, transgenic high expression of IL-4 under the
influence of an immunoglobulin promoter in
(NZW × C57B/6.Yaa)F1 mice was protective [56]. In
addition, administration of IL-6 promoted, and anti-IL-6
inhibited, the B × W and MRL-Faslpr disease [57,58].
Finally, anti-IL-10 treatment ameliorated disease in B × W
mice, presumably by upregulating TNF-a [59].
Conclusion
The discovery of the Th1-vs-Th2 dichotomy provided the
paradigm according to which cell-mediated autoimmune
diseases engage Th1 cells and their respective cytokines,
while humorally mediated autoimmune diseases engage
Th2 cells and their respective cytokines. Evidence
reviewed above, primarily on the role of IFN-g in lupus
pathogenesis, appears to contradict this paradigm. Chal-
lenges to this hypothesis have also been provided by evi-
dence from other autoimmune diseases. For example, IFN-g
was also shown to be required in the classic autoantibody-
mediated disease myasthenia gravis, whereas IL-4 was not
[60,61]. Furthermore, both Th1 and Th2 reportedly affect
the severity of disease in the cell-mediated autoimmune
diabetes of nonobese diabetic mice. Thus, depending on
the experimental conditions, IFN-g was both detrimental
and beneficial [62,63], pancreatic IL-4 expression was pro-
tective [64], islet-specific expression of IL-10 accelerated
disease [65] while systemic treatment with IL-10 prevented
it [66], and deletion of the IL-10 gene was without effect
[67] in this model. It appears, therefore, that both Th1 and
Th2 cytokines can modify a given autoimmune disease
depending on various factors, such as stage of the disease
and timing of treatment, local vs systemic expression, and
genetic background. Overall, it seems that the effects of
cytokines in autoimmune syndromes cannot be dogmati-
cally predicted, and their effects can be much more
complex than the simplistic Th1-vs-Th2 definition dictates.
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